Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD.

Published on Nov 6, 2019in The Journal of Clinical Endocrinology and Metabolism5.605
路 DOI :10.1210/clinem/dgz172
Stergios A. Polyzos32
Estimated H-index: 32
(A.U.Th.: Aristotle University of Thessaloniki),
Nikolaos Perakakis9
Estimated H-index: 9
(BIDMC: Beth Israel Deaconess Medical Center)
+ 5 AuthorsChristos S. Mantzoros106
Estimated H-index: 106
(BIDMC: Beth Israel Deaconess Medical Center)
AIMS: To investigate circulating levels and liver gene expression of 3 hormonal pathways associated with obesity, insulin resistance, and inflammation to identify leads towards potential diagnostic markers and therapeutic targets in patients with nonalcoholic fatty liver disease (NAFLD). METHODS: We compared circulating levels of (1) proglucagon-derived hormones (glucagon-like peptide [GLP]-1, GLP-2, glicentin, oxyntomodulin, glucagon, major proglucagon fragment [MPGF]), (2) follistatins-activins (follistatin-like [FSTL]3, activin B), (3) IGF axis (insulin-like growth factor [IGF]-1, total and intact IGF binding protein [IGFBP]-3 and IGFBP-4, and pregnancy-associated plasma protein [PAPP]-A) in 2 studies: (1) 18 individuals with early stage NAFLD versus 14 controls (study 1; early NAFLD study) and in (2) 31 individuals with biopsy proven NAFLD (15 with simple steatosis [SS] and 16 with nonalcoholic steatohepatitis [NASH]), vs 50 controls (24 lean and 26 obese) (study 2). Liver gene expression was assessed in 22 subjects (12 controls, 5 NASH, 5 NASH-related cirrhosis). RESULTS: Patients in early stages of NAFLD demonstrate higher fasting MPGF and lower incremental increase of glicentin during oral glucose tolerance test than controls. In more advanced stages, FSTL3 levels are higher in NASH than simple steatosis and, within NAFLD patients, in those with more severe lobular and portal inflammation. The IGF-1/intact IGFBP-3 ratio is lower in patients with liver fibrosis. Genes encoding follistatin, activin A, activin B, and the IGF-1 receptor are higher in NASH. CONCLUSION: MPGF and glicentin may be involved in early stages of NAFLD, whereas FSTL3 and IGF-1/intact IGFBP3 in the progression to NASH and liver fibrosis respectively, suggesting potential as diagnostic markers or therapeutic targets.
  • References (45)
  • Citations (0)
馃摉 Papers frequently viewed together
46 Citations
31 Citations
13 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Zobair M. Younossi (Inova Health System)H-Index: 84
#2Frank TackeH-Index: 66
Last. Miriam B. Vos (Emory University)H-Index: 27
view all 11 authors...
44 CitationsSource
#1Dario Tuccinardi (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 2
#2Olivia M. Farr (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 20
Last. Christos S. Mantzoros (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 106
view all 10 authors...
Lorcaserin is a serotonin 2c receptor agonist that promotes weight loss while contributing to the prevention and improvement of type 2 diabetes and improvement of atherogenic lipid profiles, without higher rates of major cardiovascular events. The full spectrum of possible lorcaserin-induced improvements in cardiometabolic health remains to be clarified. Thus, we investigated the way in which lorcaserin treatment may alter cardiovascular disease risk, either independently or through changes in b...
3 CitationsSource
#1Norbert Stefan (University of T眉bingen)H-Index: 64
#2Hu H盲ring (University of T眉bingen)H-Index: 88
Last. Kenneth Cusi (UF: University of Florida)H-Index: 49
view all 3 authors...
Summary The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing worldwide. In some patients with NAFLD, isolated steatosis can progress to advanced stages with non-alcoholic steatohepatitis (NASH) and fibrosis, increasing the risk of cirrhosis and hepatocellular carcinoma. Furthermore, NAFLD is believed to be involved in the pathogenesis of common disorders such as type 2 diabetes and cardiovascular disease. In this Review, we highlight novel concepts related to diagnosis, risk...
29 CitationsSource
#1Nikolaos Perakakis (Harvard University)H-Index: 9
#2Alexander Kokkinos (UoA: National and Kapodistrian University of Athens)H-Index: 15
Last. Christos S. Mantzoros (Harvard University)H-Index: 106
view all 8 authors...
3 CitationsSource
#1Nikolaos Perakakis (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 9
#2Vassilis Mougios (A.U.Th.: Aristotle University of Thessaloniki)H-Index: 28
Last. Christos S. Mantzoros (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 106
view all 8 authors...
4 CitationsSource
Abstract Insulin-like growth factor (IGF) binding protein-4 (IGFBP-4) is a modulator of the IGF system, exerting both inhibitory and stimulatory effects on IGF-induced cellular growth. IGFBP-4 is the principal substrate for the enzyme pregnancy-associated plasma protein-A (PAPP-A). Through IGF-dependent cleavage of IGFBP-4 in the vicinity of the IGF receptor, PAPP-A is able to increase IGF bioavailability and stimulate IGF-mediated growth. Recently, the stanniocalcins (STCs) were identified as n...
7 CitationsSource
#1Rongya Tao (Harvard University)H-Index: 15
#2Caixia Wang (Harvard University)H-Index: 1
Last. Morris F. White (Harvard University)H-Index: 105
view all 13 authors...
Unsuppressed hepatic glucose production (HGP) contributes substantially to glucose intolerance and diabetes, which can be modeled by the genetic inactivation of hepatic insulin receptor substrate 1 (Irs1) and Irs2 (LDKO mice). We previously showed that glucose intolerance in LDKO mice is resolved by hepatic inactivation of the transcription factor FoxO1 (that is, LTKO mice)鈥攅ven though the liver remains insensitive to insulin. Here, we report that insulin sensitivity in the white adipose tissue ...
17 CitationsSource
#1Chrysoula Boutari (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 2
#2Nikolaos Perakakis (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 9
Last. Christos S. Mantzoros (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 106
view all 3 authors...
15 CitationsSource
#1Daniel J. DruckerH-Index: 106
#2Joel F. HabenerH-Index: 100
Last. Jens J. HolstH-Index: 152
view all 3 authors...
49 CitationsSource
#1Wenhuan Feng (NU: Nanjing University)H-Index: 6
#2Caixia Gao (Nanjing University of Chinese Medicine)H-Index: 3
Last. Dalong Zhu (NU: Nanjing University)H-Index: 22
view all 9 authors...
Background The aim of the present study was to compare the effects of gliclazide, liraglutide, and metformin in type 2 diabetes mellitus (T2DM) patients with non-alcoholic fatty liver disease (NAFLD). Methods Eighty-seven subjects were randomized to receive liraglutide, metformin, or gliclazide for 24 weeks. Primary outcomes included HbA1c levels, intrahepatic fat (IHF) content, and liver function. Results Both HbA1c levels and IHF content were reduced after treatment in all three groups. Howeve...
21 CitationsSource
Cited By0